Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00351533 · ClinicalTrials.gov registry record · Phase 2
A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT00351533 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 90 participants.
The verdict
NCT00351533, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether fish oil (containing omega-3 fatty acids) given enterally is safe and effective in reducing lung and systemic inflammation seen in acute lung injury.
Interventions
- DRUG Fish oil (eicosapentaenoic acid and docosahexanoic acid)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2006-07 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00351533
The ClinicalTrials.gov registry entry for NCT00351533 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fish oil (eicosapentaenoic acid and docosahexanoic acid) is the first listed.
NCT00351533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00351533 about?
NCT00351533 is a clinical study titled "A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)". The purpose of this study is to determine whether fish oil (containing omega-3 fatty acids) given enterally is safe and effective in reducing lung and systemic inflammation seen in acute lung injury.
What is the current status of trial NCT00351533?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2006-07. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00351533?
The interventions under investigation include: Fish oil (eicosapentaenoic acid and docosahexanoic acid) (DRUG).
Who is sponsoring clinical trial NCT00351533?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.